Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00423254
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:03.299082+00:00
Published At
2010-08-03T00:00:00+00:00
Record Updated At
2010-08-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ovarian", "Melanoma", "Renal", "Prostate", "Colorectal", "Endometrial Carcinoma", "Cervical Carcinoma", "Testicular Cancer", "Thyroid Cancer", "Small Cell Lung Carcinoma", "Mesothelioma", "Breast Carcinoma", "Esophageal Carcinoma", "Gastric Cancer", "Pancreatic Carcinoma", "Neuroendocrine Cancer", "Liver Cancer", "Gallbladder Cancer", "Biliary Tract Cancer", "Anal Carcinoma", "Bone Sarcomas", "Soft Tissue Sarcomas", "Carcinoma of Unknown Origin, Primary"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2010-08-03"
protocolSection.identificationModule.nctId
"NCT00423254"
protocolSection.identificationModule.officialTitle
"A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ovarian (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Renal (protocolSection.conditionsModule.conditions)
  • Prostate (protocolSection.conditionsModule.conditions)
  • Colorectal (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Carcinoma (protocolSection.conditionsModule.conditions)
  • Testicular Cancer (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Esophageal Carcinoma (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Carcinoma (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Cancer (protocolSection.conditionsModule.conditions)
  • Liver Cancer (protocolSection.conditionsModule.conditions)
  • Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Biliary Tract Cancer (protocolSection.conditionsModule.conditions)
  • Anal Carcinoma (protocolSection.conditionsModule.conditions)
  • Bone Sarcomas (protocolSection.conditionsModule.conditions)
  • Soft Tissue Sarcomas (protocolSection.conditionsModule.conditions)
  • Carcinoma of Unknown Origin, Primary (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.